These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18814764)

  • 1. [Coronary drug-eluting stents in diabetic patients].
    Nyssen A; Legrand V; Scheen AJ
    Rev Med Suisse; 2008 Aug; 4(168):1806-10. PubMed ID: 18814764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Benefit-risk ratio of coronary drug-eluting stents: 2nd part: evaluation in the diabetic population].
    Nyssen A; Legrand V; Scheen AJ
    Rev Med Liege; 2008 Nov; 63(11):654-61. PubMed ID: 19112990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program.
    Lasala JM; Cox DA; Morris DL; Breall JA; Mahoney PD; Horwitz PA; Shaw D; Hood KL; Mandinov L; Dawkins KD
    Am J Cardiol; 2009 Jun; 103(12):1663-71. PubMed ID: 19539073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry).
    Kaltoft A; Jensen LO; Maeng M; Tilsted HH; Thayssen P; Bøttcher M; Lassen JF; Krusell LR; Rasmussen K; Hansen KN; Pedersen L; Johnsen SP; Sørensen HT; Thuesen L
    J Am Coll Cardiol; 2009 Feb; 53(8):658-64. PubMed ID: 19232897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
    Lee JY; Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Park SW; Park SJ
    J Am Coll Cardiol; 2009 Aug; 54(9):853-9. PubMed ID: 19695467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy insight: diabetes and drug-eluting stents.
    Legrand V
    Nat Clin Pract Cardiovasc Med; 2007 Mar; 4(3):143-50. PubMed ID: 17330126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
    Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
    Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.
    Onuma Y; Kukreja N; Piazza N; Eindhoven J; Girasis C; Schenkeveld L; van Domburg R; Serruys PW;
    J Am Coll Cardiol; 2009 Jul; 54(3):269-76. PubMed ID: 19589442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial.
    Daemen J; Kuck KH; Macaya C; LeGrand V; Vrolix M; Carrie D; Sheiban I; Suttorp MJ; Vranckx P; Rademaker T; Goedhart D; Schuijer M; Wittebols K; Macours N; Stoll HP; Serruys PW;
    J Am Coll Cardiol; 2008 Dec; 52(24):1957-67. PubMed ID: 19055986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
    Lee CW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Yun SC; Seong IW; Lee JH; Lee NH; Cho YH; Cheong SS; Lim DS; Yang JY; Lee SG; Kim KS; Yoon J; Jeong MH; Seung KB; Hong TJ; Park SJ;
    Am J Cardiol; 2009 Nov; 104(10):1370-6. PubMed ID: 19892052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents.
    Kim YH; Park DW; Lee SW; Yun SC; Lee CW; Hong MK; Park SW; Seung KB; Gwon HC; Jeong MH; Jang Y; Kim HS; Seong IW; Park HS; Ahn T; Chae IH; Tahk SJ; Chung WS; Park SJ;
    Circulation; 2009 Aug; 120(5):400-7. PubMed ID: 19620506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry.
    Garg P; Normand SL; Silbaugh TS; Wolf RE; Zelevinsky K; Lovett A; Varma MR; Zhou Z; Mauri L
    Circulation; 2008 Nov; 118(22):2277-85, 7p following 2285. PubMed ID: 19001019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a preferable DES in diabetic patients? A critical appraisal of the evidence.
    Byrne RA; Kastrati A
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):944-9. PubMed ID: 19021280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
    Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A
    Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major adverse cardiac events at follow-up after bare-metal stenting versus drug-eluting stenting in ST-elevated myocardial infarction.
    Pierre-Louis B; Aronow WS; Palaniswamy C; Singh T; Ahn C; Asija A; Weiss MB; Kalapatapu K; Pucillo AL; Monsen CE
    Am J Cardiol; 2009 Jun; 103(12):1672-4. PubMed ID: 19539074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.